OpenAI has fired an employee over the employee’s activity on prediction markets, including Polymarket, the company confirmed to Wired. The employee used confidential OpenAI information in connection with the trades made, the company alleges. OpenAI didn’t release the name of the employee. However, a spokesperson said that such actions violated a company policy that bans workers from using inside information for personal gain, including on prediction markets. Prediction markets like Polymarket and Kals ...

Edmonton, Alberta--(Newsfile Corp. - February 27, 2026) - TrustBIX Inc. (TSXV: TBIX) ("TrustBIX" or the "Company") announced today financial results for the first quarter ended December 31, 2025, and the related Management's Discussion and Analysis ("MD&A").For the three months ended December 31, 2025, compared to the same period in 2024, the Company reported results from continuing operations of:Net loss and comprehensive loss of $104,214, improved by $59,265 (36.3%) from $163,479 in Q1 2025;Operating exp ...

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Paysafe Limited ("Paysafe†or the "Company†) (NYSE:PSFE) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. [CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION] What Should I Do? Investors have until April 7, 2026 to ask the Court to appoint them as lead plaintiff. Courts do n ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Franklin BSP Realty Trust, Inc. ("Franklin†or the "Company†) (NYSE:FBRT) securities during the period of November 5, 2024 through February 22, 2026, inclusive ("the Class Period†). If you suffered a loss on your Franklin investments, you have until April 27, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff appli. ...

TAMPA, Fla.--(BUSINESS WIRE)--The Baldwin Group ("Baldwin†or the "Company†) (NASDAQ: BWIN), a leading independent insurance brokerage and advisory firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced a long-planned leadership transition within its Underwriting, Capacity, & Technology Solutions ("UCTS†) operating group, effective January 1, 2027. Amy Carlisle will become Chief Executive Officer of UCTS, succeeding Jim Roche, who will assume the ...

VANCOUVER, BC / ACCESS Newswire / February 27, 2026 / Global Education Communities Corp. ("GECC" or the "Company") (TSX:GEC)(OTCQX International:GECSF) reports the director election voting results from its annual general meeting held today. All of the director nominees, as listed in the management information circular dated January 12, 2026, were elected. ...

Stocks are falling, inflation is growing, the Fed may be hamstrung. What else could go wrong? ...

Core Viewpoint - The U.S. FDA has granted accelerated approval for YUVIWEL (navepegritide), the first once-weekly treatment for increasing linear growth in children aged 2 and older with achondroplasia, contingent upon further verification of clinical benefits in confirmatory trials [1][9]. Company Overview - Ascendis Pharma A/S is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform, headquartered in Copenhagen, Denmark [17]. Product Details - YUVIWEL is a prodrug of C-type natriuretic peptide (CNP) designed to provide continuous systemic exposure to CNP, counteracting overactive FGFR3 signaling in achondroplasia [2]. - The approval is based on data from three randomized, double-blind, placebo-controlled clinical trials, including pivotal data from the ApproaCH Trial [3][4]. Market Impact - YUVIWEL is expected to be commercially available in the early part of Q2 2026, with a suite of patient services planned through the Ascendis Signature Access Program (A.S.A.P.) [4][6]. - The FDA also granted a Rare Pediatric Disease Priority Review Voucher in connection with the approval, which can expedite future drug applications [5]. Community Engagement - Advocacy groups, such as Little People of America, emphasize the importance of including the voices of individuals with dwarfism in discussions about treatment options like YUVIWEL [3].

Stocks' Winter of Discontent Could Linger Well Past the Season. Plus, Picks Among BDCs. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Stocks' Season of Discontent Could Linger Well Past Winter. Plus, Picks Among BDCs.By [Randall W. Forsyt ...

Warren Buffett stepped down as Berkshire Hathaway's (NYSE: BRKB)(NYSE: BRKB) CEO at the end of 2025, passing the reins to Greg Abel. While Buffett remains at Berkshire as the chairman of the company's board of directors, his departure from the CEO position marks the end of a legendary and highly lauded era. Read on for a look at three stocks Berkshire heavily sold out of in the fourth quarter -- and one high-yield dividend stock it continued to pile into. Image source: The Motley Fool. Will AI create the ...